Susquehanna International Group’s Matinas BioPharma MTNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.16K Sell
14,328
-6,785
-32% -$4.25K ﹤0.01% 12967
2025
Q4
$12.4K Buy
+21,113
New +$24.9K ﹤0.01% 12035
2025
Q2
Sell
-25,610
Closed -$13.3K 13340
2025
Q1
$13.3K Buy
25,610
+1,808
+8% +$1.07K ﹤0.01% 12193
2024
Q4
$12.1K Buy
+23,802
New +$36.2K ﹤0.01% 11972
2024
Q1
Sell
-275
Closed -$2.97K 12911
2023
Q4
$2.97K Buy
+275
New +$3.1K ﹤0.01% 12153
2023
Q2
Sell
-295
Closed -$6.92K 12749
2023
Q1
$6.92K Sell
295
-286
-49% -$7.23K ﹤0.01% 12260
2022
Q4
$14.5K Buy
+581
New +$19.3K ﹤0.01% 11856
2022
Q1
Sell
-1,191
Closed -$60K 13619
2021
Q4
$60K Buy
+1,191
New +$63.7K ﹤0.01% 12448
2021
Q3
Sell
-239
Closed -$9K 13256
2021
Q2
$9K Sell
239
-6,366
-96% -$274K ﹤0.01% 12446
2021
Q1
$347K Buy
6,605
+6,065
+1,123% +$407K ﹤0.01% 10310
2020
Q4
$37K Sell
540
-753
-58% -$34.9K ﹤0.01% 10814
2020
Q3
$50K Buy
+1,293
New +$51.4K ﹤0.01% 10198
2020
Q2
Sell
-25,828
Closed -$775K 10626
2020
Q1
$775K Buy
25,828
+14,122
+121% +$853K ﹤0.01% 5956
2019
Q4
$1.33M Buy
+11,706
New +$678K ﹤0.01% 5002
2019
Q3
Sell
-1,803
Closed -$77K 10600
2019
Q2
$77K Sell
1,803
-3,353
-65% -$161K ﹤0.01% 9710
2019
Q1
$281K Buy
+5,156
New +$278K ﹤0.01% 7325
2018
Q2
Sell
-369
Closed -$14K 10100
2018
Q1
$14K Buy
+369
New +$19.5K ﹤0.01% 9162
2017
Q2
Sell
-693
Closed -$96K 9581
2017
Q1
$96K Buy
+693
New +$113K ﹤0.01% 8405

Other funds holding MTNB

Susquehanna International Group's MTNB Position: Q1 2026 in Review

Susquehanna International Group reduced its Matinas BioPharma (MTNB) stake by 32% in Q1 2026, selling an estimated $4.25K and leaving 14,328 shares worth $7.16K. The position accounts for ﹤0.01% of the portfolio, ranked #12967.

Susquehanna International Group first reported a position in MTNB in Q1 2017 and has held it in 18 quarters since. The position peaked at $1.33M in Q4 2019. 28 funds tracked by Wall St. Rank hold MTNB as of Q1 2026.

  • Susquehanna International Group held 14,328 shares of Matinas BioPharma worth $7.16K as of Q1 2026.
  • Susquehanna International Group sold 6,785 Matinas BioPharma shares in Q1 2026, an estimated $4.25K.
  • Matinas BioPharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12967 holding.
  • Susquehanna International Group first reported a position in Matinas BioPharma in Q1 2017 and has held it in 18 quarters since.
  • Susquehanna International Group's Matinas BioPharma position peaked at $1.33M in Q4 2019.
  • 28 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.